UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The role of ADAMTS13 testing in the diagnosis and management of thrombotic microangiopathies and thrombosis

Blood, 2018-08, Vol.132 (9), p.903-910

2018

Volltextzugriff (PDF)

None of the above: thrombotic microangiopathy beyond TTP and HUS

Blood, 2017-05, Vol.129 (21), p.2857-2863

2017

Volltextzugriff (PDF)

How targeted therapy disrupts the treatment paradigm for acquired TTP: the risks, benefits, and unknowns

Blood, 2019-08, Vol.134 (5), p.415-420

2019

Volltextzugriff (PDF)

Five years of caplacizumab – lessons learned and remaining controversies in immune-mediated thrombotic thrombocytopenic purpura

Journal of thrombosis and haemostasis, 2023-10, Vol.21 (10), p.2718-2725

2023

Volltextzugriff (PDF)

The impact of TTP in the brain

Blood, 2023-07, Vol.142 (4), p.307-308

Masias, Camila

2023

Volltextzugriff (PDF)

Management of bleeding risk in patients who receive anticoagulant therapy for venous thromboembolism: Communication from the ISTH SSC Subcommittee on Predictive and Diagnostic Variables in Thrombotic Disease

Journal of thrombosis and haemostasis, 2022-08, Vol.20 (8), p.1910-1919

2022

Volltextzugriff (PDF)

Should older patients with low weight and CKD receive full-dose DOACs for treatment of acute proximal DVT?

Hematology, 2023-12, Vol.2023 (1), p.614-616

2023

Volltextzugriff (PDF)

Cyclosporine or steroids as an adjunct to plasma exchange in the treatment of immune-mediated thrombotic thrombocytopenic purpura

Blood advances, 2017-10, Vol.1 (23), p.2075-2082

2017

Volltextzugriff (PDF)

A systematic review of biomarkers among hospitalized patients with COVID‐19 predictive of venous thromboembolism: A communication from the Predictive and Diagnostic Variables Scientific and Standardization Committee of the ISTH

Research and practice in thrombosis and haemostasis, 2022-08, Vol.6 (6), p.e12786-n/a, Article e12786

2022

Volltextzugriff (PDF)

Genetic Landscape of Thrombotic Microangiopathies with Focus on Plasminogen Mutation Variants

Blood, 2023-11, Vol.142 (Supplement 1), p.4002-4002

2023

Volltextzugriff (PDF)

Pregnancy and Immune Mediated Thrombotic Thrombocytopenic Purpura (iTTP); A Descriptive Analysis from the U.S. Thrombotic Microangiopathy (USTMA) Registry

Blood, 2023-11, Vol.142 (Supplement 1), p.4009-4009

2023

Volltextzugriff (PDF)

Use of Preemptive Treatment for Immune Thrombotic Thrombocytopenic Purpura: A Matched Survival Analysis

Blood, 2021-11, Vol.138 (Supplement 1), p.2084-2084

2021

Volltextzugriff (PDF)

Breast cancer subtypes in Chinese Americans: A study from the Mount Sinai Health System

Journal of clinical oncology, 2014-09, Vol.32 (26_suppl), p.39-39

2014

Volltextzugriff (PDF)

Interrelationship between ADAMTS13 activity, von Willebrand factor, and complement activation in remission from immune‐mediated trhrombotic thrombocytopenic purpura

British journal of haematology, 2020-04, Vol.189 (1), p.e18-e20

2020

Volltextzugriff (PDF)

When you think you should transfuse…don’t

Laboratory medicine, 2024-09, Vol.55 (5), p.663-666

2024

Volltextzugriff (PDF)

A Pilot Study on Biomarkers of Vascular Injury in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura

Blood, 2019-11, Vol.134 (Supplement_1), p.2377-2377

2019

Volltextzugriff (PDF)

Severely Deficient ADAMTS13 Activity Predicts Relapse of Immune-Mediated Thrombotic Thrombocytopenic Purpura in Pregnancy

Blood, 2019-11, Vol.134 (Supplement_1), p.1098-1098

2019

Volltextzugriff (PDF)

Relapse Prediction Model for Immune-Mediated Thrombotic Thrombocytopenic Purpura

Blood, 2020-11, Vol.136 (Supplement 1), p.8-9

2020

Volltextzugriff (PDF)

No major differences in outcomes between the initial and relapse episodes in patients with thrombotic thrombocytopenic purpura: The experience from the Ohio State University Registry

American journal of hematology, 2018-03, Vol.93 (3), p.E73-E75

2018

Volltextzugriff (PDF)

Use of patient-reported outcome measures in patients with venous thromboembolism: communication from the ISTH SSC Subcommittee on Predictive and Diagnostic Variables in Thrombotic Disease

Journal of thrombosis and haemostasis, 2023-10, Vol.21 (10), p.2953-2962

2023

Volltextzugriff (PDF)

Novel therapies in thrombotic thrombocytopenic purpura

Research and practice in thrombosis and haemostasis, 2018-01, Vol.2 (1), p.19-26

2018

Volltextzugriff (PDF)

Race, rituximab, and relapse in TTP

Blood, 2022-09, Vol.140 (12), p.1335-1344

2022

Volltextzugriff (PDF)

Caplacizumab Frontline Added to Therapeutic Plasma Exchange and Immunosuppression Prevents Unfavorable Outcomes in Immune-Mediated TTP: An International Real-World Study of the TTP-IWG (The Capla 500 Project)

Blood, 2023-11, Vol.142 (Supplement 1), p.2636-2636

2023

Volltextzugriff (PDF)

Thrombotic thrombocytopenic purpura: 100 years of research on Moschcowitz syndrome

Blood, 2024-09, Vol.144 (11), p.1143-1152

2024

Volltextzugriff (PDF)

Development and validation of a risk model for hospital-acquired venous thrombosis: the Medical Inpatients Thrombosis and Hemostasis study

Journal of thrombosis and haemostasis, 2024-02, Vol.22 (2), p.503-515

2024

Volltextzugriff (PDF)

1 – 25 von 32

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(31)
Mit Volltextzugriff
(28)

Publikationsform

Artikel
(32)

Sprache

Englisch
(31)
Spanisch
(1)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The role of ADAMTS13 testing in the diagnosis and management of thrombotic microangiopathies and thrombosis

None of the above: thrombotic microangiopathy beyond TTP and HUS

How targeted therapy disrupts the treatment paradigm for acquired TTP: the risks, benefits, and unknowns

Five years of caplacizumab – lessons learned and remaining controversies in immune-mediated thrombotic thrombocytopenic purpura

The impact of TTP in the brain

Management of bleeding risk in patients who receive anticoagulant therapy for venous thromboembolism: Communication from the ISTH SSC Subcommittee on Predictive and Diagnostic Variables in Thrombotic Disease

Should older patients with low weight and CKD receive full-dose DOACs for treatment of acute proximal DVT?

Cyclosporine or steroids as an adjunct to plasma exchange in the treatment of immune-mediated thrombotic thrombocytopenic purpura

A systematic review of biomarkers among hospitalized patients with COVID‐19 predictive of venous thromboembolism: A communication from the Predictive and Diagnostic Variables Scientific and Standardization Committee of the ISTH

Genetic Landscape of Thrombotic Microangiopathies with Focus on Plasminogen Mutation Variants

Pregnancy and Immune Mediated Thrombotic Thrombocytopenic Purpura (iTTP); A Descriptive Analysis from the U.S. Thrombotic Microangiopathy (USTMA) Registry

Use of Preemptive Treatment for Immune Thrombotic Thrombocytopenic Purpura: A Matched Survival Analysis

Breast cancer subtypes in Chinese Americans: A study from the Mount Sinai Health System

Interrelationship between ADAMTS13 activity, von Willebrand factor, and complement activation in remission from immune‐mediated trhrombotic thrombocytopenic purpura

When you think you should transfuse…don’t

A Pilot Study on Biomarkers of Vascular Injury in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura

Severely Deficient ADAMTS13 Activity Predicts Relapse of Immune-Mediated Thrombotic Thrombocytopenic Purpura in Pregnancy

Relapse Prediction Model for Immune-Mediated Thrombotic Thrombocytopenic Purpura

No major differences in outcomes between the initial and relapse episodes in patients with thrombotic thrombocytopenic purpura: The experience from the Ohio State University Registry

Use of patient-reported outcome measures in patients with venous thromboembolism: communication from the ISTH SSC Subcommittee on Predictive and Diagnostic Variables in Thrombotic Disease

Novel therapies in thrombotic thrombocytopenic purpura

Race, rituximab, and relapse in TTP

Caplacizumab Frontline Added to Therapeutic Plasma Exchange and Immunosuppression Prevents Unfavorable Outcomes in Immune-Mediated TTP: An International Real-World Study of the TTP-IWG (The Capla 500 Project)

Thrombotic thrombocytopenic purpura: 100 years of research on Moschcowitz syndrome

Development and validation of a risk model for hospital-acquired venous thrombosis: the Medical Inpatients Thrombosis and Hemostasis study

Suchergebnisse filtern